ASCO: Revolution Medicines confident in RAS leadership as rivals square up
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancre...
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year. But even as competitors swirl, RevMed is confident that it can maintain the leadership position it has worked so hard to obtain.